Dataset from BI 695501 Versus Humira® in Patients With Active Crohn's Disease: a Randomized, Double-blind, Multicenter, Parallel Group, Exploratory Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Primary Objective:

The primary objective of this trial is to compare the clinical efficacy of BI 695501 with
EU-approved Humira® in patients with active Crohn's disease (CD).

Secondary Objectives:

The secondary objectives of this trial are to compare the efficacy and safety of BI 695501
with EU-approved Humira® across the induction and maintenance phases.

主要试验目的：
本试验的主要目的为对比BI 695501与欧盟获批的修美乐（Humira®）在活动性克罗恩病（Crohn's Disease, CD）患者中的临床疗效。

次要试验目的：
本试验的次要目的为在诱导治疗与维持治疗阶段中，对比BI 695501与欧盟获批的修美乐（Humira®）的疗效与安全性。